A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function. 2003

Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
Department of Molecular Immunology, Institute of Basic Medical Sciences, 27 Taiping Road, Beijing 100850, P.R. China.

Elevated erbB2 expression is detected in many in situ and invasive human ductal carcinomas. Anti-erbB2 antibody directed at the extracellular domain of erbB2 can result in an antitumor response in some patients with tumors overexpressing erbB2 oncoprotein. By combining interleukin 2 (IL-2) activities with a tumor specific antibody, immunotherapy of tumors might be more effective in the future. In this study, a fusion protein consisting of erbB2 single chain antibody (scFv), Fc fragment of human IgG1 and IL-2 was constructed. The molecular weight of fusion proteins is 66 kDa, only one third of whole antibody-IL-2 fusion protein or 44% whole Ig molecule. The fusion proteins retained the activities of both antigen binding and IL-2. The scFv-Fc-IL-2 fusion protein may have advantages over whole antibody-IL-2 fusion proteins, such as smaller molecule, better activity of penetration, more favorable pharmacokinetic properties.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007128 Immunoglobulin Fragments Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques. Antibody Fragment,Antibody Fragments,Ig Fragment,Ig Fragments,Immunoglobulin Fragment,Fragment, Antibody,Fragment, Ig,Fragment, Immunoglobulin,Fragments, Antibody,Fragments, Ig,Fragments, Immunoglobulin
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
November 2000, Journal of immunology (Baltimore, Md. : 1950),
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
October 2007, Acta pharmacologica Sinica,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
February 2013, International journal of oncology,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
July 2004, Biochemical and biophysical research communications,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
October 1998, Journal of immunology (Baltimore, Md. : 1950),
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
January 2003, Journal of bioscience and bioengineering,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
June 2004, International journal of cancer,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
February 2007, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
April 2004, Cancer immunology, immunotherapy : CII,
Ming Shi, and Zhigang Xie, and Jiannan Feng, and Yingxun Sun, and Ming Yu, and Beifen Shen, and Ning Guo
November 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!